These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30168000)

  • 21. Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms.
    Lindfelt T; O'Brien J; Song JC; Patel R; Winslow DL
    Ann Pharmacother; 2010 Oct; 44(10):1572-8. PubMed ID: 20841522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sleep quality in efavirenz-treated Chinese HIV patients - comparing between GT and GG genotype of CYP2B6-516 G/T polymorphisms.
    Lee SS; To KW; Lee MP; Wong NS; Chan DP; Li PC; Cheung SW; Chan RC
    Int J STD AIDS; 2014 Mar; 25(3):193-200. PubMed ID: 23970651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa.
    Cohen K; Grant A; Dandara C; McIlleron H; Pemba L; Fielding K; Charalombous S; Churchyard G; Smith P; Maartens G
    Antivir Ther; 2009; 14(5):687-95. PubMed ID: 19704172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry.
    Wang PF; Neiner A; Kharasch ED
    Drug Metab Dispos; 2019 Oct; 47(10):1195-1205. PubMed ID: 31324697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe.
    Nyakutira C; Röshammar D; Chigutsa E; Chonzi P; Ashton M; Nhachi C; Masimirembwa C
    Eur J Clin Pharmacol; 2008 Apr; 64(4):357-65. PubMed ID: 18057928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.
    Wyen C; Hendra H; Siccardi M; Platten M; Jaeger H; Harrer T; Esser S; Bogner JR; Brockmeyer NH; Bieniek B; Rockstroh J; Hoffmann C; Stoehr A; Michalik C; Dlugay V; Jetter A; Knechten H; Klinker H; Skaletz-Rorowski A; Fätkenheuer G; Egan D; Back DJ; Owen A;
    J Antimicrob Chemother; 2011 Sep; 66(9):2092-8. PubMed ID: 21715435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection.
    Meng X; Yin K; Wang J; Dong P; Liu L; Shen Y; Shen L; Ma Q; Lu H; Cai W
    PLoS One; 2015; 10(6):e0130583. PubMed ID: 26107645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
    Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Mugusi S; Amogne W; Yimer G; Riedel KD; Janabi M; Aderaye G; Mugusi F; Bertilsson L; Aklillu E; Burhenne J
    PLoS One; 2013; 8(7):e67946. PubMed ID: 23861838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of Cytochrome P450 2B6 Single Nucleotide Polymorphism in an HIV-Positive Cohort in Jos, Nigeria: Implication for HIV Therapy.
    Isaac AO; Wetkos DD; Oche AO; Godwin I; Phyllis K; John AC
    Niger J Clin Pract; 2020 Dec; 23(12):1736-1743. PubMed ID: 33355828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1.
    Manosuthi W; Sukasem C; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
    Antimicrob Agents Chemother; 2014; 58(4):2268-73. PubMed ID: 24492364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation.
    Powers V; Ward J; Gompels M
    HIV Med; 2009 Sep; 10(8):520-3. PubMed ID: 19486190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.
    Holzinger ER; Grady B; Ritchie MD; Ribaudo HJ; Acosta EP; Morse GD; Gulick RM; Robbins GK; Clifford DB; Daar ES; McLaren P; Haas DW
    Pharmacogenet Genomics; 2012 Dec; 22(12):858-67. PubMed ID: 23080225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.
    Kwara A; Lartey M; Sagoe KW; Xexemeku F; Kenu E; Oliver-Commey J; Boima V; Sagoe A; Boamah I; Greenblatt DJ; Court MH
    J Clin Pharmacol; 2008 Sep; 48(9):1032-40. PubMed ID: 18728241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.
    Griesel R; Maartens G; Chirehwa M; Sokhela S; Akpomiemie G; Moorhouse M; Venter F; Sinxadi P
    Clin Infect Dis; 2021 Dec; 73(11):e3902-e3909. PubMed ID: 32960272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy.
    Lee KY; Lin SW; Sun HY; Kuo CH; Tsai MS; Wu BR; Tang SY; Liu WC; Chang SY; Hung CC
    PLoS One; 2014; 9(2):e88497. PubMed ID: 24551111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipid-based nutrient supplements do not affect efavirenz but lower plasma nevirapine concentrations in Ethiopian adult HIV patients.
    Abdissa A; Olsen MF; Yilma D; Tesfaye M; Girma T; Christiansen M; Hagen CM; Wiesner L; Castel S; Aseffa A; McIlleron H; Pedersen C; Friis H; Andersen AB
    HIV Med; 2015 Aug; 16(7):403-11. PubMed ID: 25974723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymorphisms in cytochrome P450 are associated with extensive efavirenz pharmacokinetics and CNS toxicities in an HIV cohort in Botswana.
    Vujkovic M; Bellamy SL; Zuppa AF; Gastonguay MR; Moorthy GS; Ratshaa B; Han X; Steenhoff AP; Mosepele M; Strom BL; Bisson GP; Aplenc R; Gross R
    Pharmacogenomics J; 2018 Sep; 18(5):678-688. PubMed ID: 29855606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High plasma efavirenz concentration and CYP2B6 polymorphisms in Thai HIV-1 infections.
    Sukasem C; Chamnanphon M; Koomdee N; Puangpetch A; Santon S; Jantararoungtong T; Prommas S; Chantratita W; Manosuthi W
    Drug Metab Pharmacokinet; 2013; 28(5):391-7. PubMed ID: 23399569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.
    Haas DW; Gebretsadik T; Mayo G; Menon UN; Acosta EP; Shintani A; Floyd M; Stein CM; Wilkinson GR
    J Infect Dis; 2009 Mar; 199(6):872-80. PubMed ID: 19239339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study.
    Olagunju A; Bolaji O; Amara A; Waitt C; Else L; Adejuyigbe E; Siccardi M; Back D; Khoo S; Owen A
    Clin Infect Dis; 2015 Aug; 61(3):453-63. PubMed ID: 25882300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.